Where did our name come from?

We’re called Q’Apel for the Qu’Appelle River, a waterway that winds through Saskatchewan, Canada. Why? Because this pristine river charts a winding path, full of twists, turns, and straightaways alike. That’s what we do, too. Our cutting-edge products—neurological catheters, specifically—are designed to navigate the twists and turns of the brain’s neurovasculature, empowering therapeutic thrombectomy and cerebral aneurysm devices to deliver life-changing outcomes.

Who We Are
View All Resources

Balloon guide catheter improves revascularization and clinical outcomes with the solitaire device analysis of the North American Solitaire Acute Stroke Registry.

October 15, 2013

Abstract, via the American Heart Association Journal:

Efficient and timely recanalization is an important goal in acute stroke endovascular therapy.

Several studies demonstrated improved recanalization and clinical outcomes with the stent retriever devices compared with the Merci device. The goal of this study was to evaluate the role of the balloon guide catheter (BGC) and recanalization success in a substudy of the North American Solitaire Acute Stroke (NASA) registry.\

Publication Link:
https://www.ahajournals.org/

Related readings.

Our utmost commitment: creating what works based specifically and urgently on what’s needed. Explore additional resources, publications, and webinars to learn more.

October 12, 2021

Q’Apel Medical, Inc. Awarded U.S. Patent for its Highly Innovative SelectFlex™ Technology

Read
August 23, 2021

Q’Apel Medical Launches Armadillo – A New Radial Artery Access Platform to Meet the Needs of Physicians and Patients

Read
August 9, 2021

Q’Apel Medical Welcomes Thomas Berryman, Chief Financial Officer

Read
July 27, 2021

Q’Apel Medical Announces Move to New Headquarters Facility in Fremont, CA

Read